These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 34512658)

  • 1. Impact of Toll-Like Receptor-Specific Agonists on the Host Immune Response to the
    Biryukov S; Dankmeyer JL; Shamsuddin Z; Velez I; Rill NO; Rosario-Acevedo R; Klimko CP; Shoe JL; Hunter M; Ward MD; Cazares LH; Fetterer DP; Bozue JA; Worsham PL; Cote CK; Amemiya K
    Front Immunol; 2021; 12():726416. PubMed ID: 34512658
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CpG oligodeoxynucleotides augment the murine immune response to the Yersinia pestis F1-V vaccine in bubonic and pneumonic models of plague.
    Amemiya K; Meyers JL; Rogers TE; Fast RL; Bassett AD; Worsham PL; Powell BS; Norris SL; Krieg AM; Adamovicz JJ
    Vaccine; 2009 Apr; 27(16):2220-9. PubMed ID: 19428836
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Complete Protection against Pneumonic and Bubonic Plague after a Single Oral Vaccination.
    Derbise A; Hanada Y; Khalifé M; Carniel E; Demeure CE
    PLoS Negl Trop Dis; 2015; 9(10):e0004162. PubMed ID: 26473734
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recombinant V antigen protects mice against pneumonic and bubonic plague caused by F1-capsule-positive and -negative strains of Yersinia pestis.
    Anderson GW; Leary SE; Williamson ED; Titball RW; Welkos SL; Worsham PL; Friedlander AM
    Infect Immun; 1996 Nov; 64(11):4580-5. PubMed ID: 8890210
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Humoral and cellular immune correlates of protection against bubonic plague by a live Yersinia pseudotuberculosis vaccine.
    Demeure CE; Derbise A; Guillas C; Gerke C; Cauchemez S; Carniel E; Pizarro-Cerdá J
    Vaccine; 2019 Jan; 37(1):123-129. PubMed ID: 30467064
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Complete Protection Against
    Zhang W; Song X; Zhai L; Guo J; Zheng X; Zhang L; Lv M; Hu L; Zhou D; Xiong X; Yang W
    Front Immunol; 2022; 13():793382. PubMed ID: 35154110
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of protective potential of Yersinia pestis outer membrane protein antigens as possible candidates for a new-generation recombinant plague vaccine.
    Erova TE; Rosenzweig JA; Sha J; Suarez G; Sierra JC; Kirtley ML; van Lier CJ; Telepnev MV; Motin VL; Chopra AK
    Clin Vaccine Immunol; 2013 Feb; 20(2):227-38. PubMed ID: 23239803
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combinatorial Viral Vector-Based and Live Attenuated Vaccines without an Adjuvant to Generate Broader Immune Responses to Effectively Combat Pneumonic Plague.
    Kilgore PB; Sha J; Hendrix EK; Motin VL; Chopra AK
    mBio; 2021 Dec; 12(6):e0322321. PubMed ID: 34872353
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sex differences in immune protection in mice conferred by heterologous vaccines for pneumonic plague.
    Davies ML; Biryukov SS; Rill NO; Klimko CP; Hunter M; Dankmeyer JL; Miller JA; Shoe JL; Mlynek KD; Talyansky Y; Toothman RG; Qiu J; Bozue JA; Cote CK
    Front Immunol; 2024; 15():1397579. PubMed ID: 38835755
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intranasal delivery of a protein subunit vaccine using a Tobacco Mosaic Virus platform protects against pneumonic plague.
    Arnaboldi PM; Sambir M; D'Arco C; Peters LA; Seegers JF; Mayer L; McCormick AA; Dattwyler RJ
    Vaccine; 2016 Nov; 34(47):5768-5776. PubMed ID: 27745954
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of an F1/V fusion protein in attenuated Salmonella typhimurium and protection of mice against plague.
    Leary SE; Griffin KF; Garmory HS; Williamson ED; Titball RW
    Microb Pathog; 1997 Sep; 23(3):167-79. PubMed ID: 9281474
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Developing subunit immunogens using B and T cell epitopes and their constructs derived from the F1 antigen of Yersinia pestis using novel delivery vehicles.
    Sabhnani L; Manocha M; Sridevi K; Shashikiran D; Rayanade R; Rao DN
    FEMS Immunol Med Microbiol; 2003 Oct; 38(3):215-29. PubMed ID: 14522457
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cell-mediated immune response and Th/Th cytokine profile of B-T constructs of F1 and V antigen of Yersinia pestis.
    Gupta G; Khan AA; Rao DN
    Scand J Immunol; 2010 Mar; 71(3):186-98. PubMed ID: 20415784
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Robust Th1 cellular and humoral responses generated by the Yersinia pestis rF1-V subunit vaccine formulated to contain an agonist of the CD137 pathway do not translate into increased protection against pneumonic plague.
    Bowen W; Batra L; Pulsifer AR; Yolcu ES; Lawrenz MB; Shirwan H
    Vaccine; 2019 Sep; 37(38):5708-5716. PubMed ID: 31416643
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oral vaccination with salmonella simultaneously expressing Yersinia pestis F1 and V antigens protects against bubonic and pneumonic plague.
    Yang X; Hinnebusch BJ; Trunkle T; Bosio CM; Suo Z; Tighe M; Harmsen A; Becker T; Crist K; Walters N; Avci R; Pascual DW
    J Immunol; 2007 Jan; 178(2):1059-67. PubMed ID: 17202369
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mutated and bacteriophage T4 nanoparticle arrayed F1-V immunogens from Yersinia pestis as next generation plague vaccines.
    Tao P; Mahalingam M; Kirtley ML; van Lier CJ; Sha J; Yeager LA; Chopra AK; Rao VB
    PLoS Pathog; 2013; 9(7):e1003495. PubMed ID: 23853602
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oral vaccination against plague using Yersinia pseudotuberculosis.
    Demeure CE; Derbise A; Carniel E
    Chem Biol Interact; 2017 Apr; 267():89-95. PubMed ID: 27046452
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Kinetics of the immune response to the (F1+V) vaccine in models of bubonic and pneumonic plague.
    Williamson ED; Stagg AJ; Eley SM; Taylor R; Green M; Jones SM; Titball RW
    Vaccine; 2007 Jan; 25(6):1142-8. PubMed ID: 17101198
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevention of pneumonic plague in mice, rats, guinea pigs and non-human primates with clinical grade rV10, rV10-2 or F1-V vaccines.
    Quenee LE; Ciletti NA; Elli D; Hermanas TM; Schneewind O
    Vaccine; 2011 Sep; 29(38):6572-83. PubMed ID: 21763383
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Purification and protective efficacy of monomeric and modified Yersinia pestis capsular F1-V antigen fusion proteins for vaccination against plague.
    Goodin JL; Nellis DF; Powell BS; Vyas VV; Enama JT; Wang LC; Clark PK; Giardina SL; Adamovicz JJ; Michiel DF
    Protein Expr Purif; 2007 May; 53(1):63-79. PubMed ID: 17293124
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.